Nexien BioPharma, Inc. (NXEN) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerNexien BioPharma, Inc. (NXEN) trades at $0.0001. Nexien BioPharma, Inc. is a pharmaceutical company based in Glendale, Colorado, focused on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for NXEN: NXEN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Nexien BioPharma, Inc. (NXEN) Healthcare & Pipeline Overview
Nexien BioPharma, Inc. is a Glendale, Colorado-based pharmaceutical company specializing in the formulation, development, and commercialization of cannabinoid-based pharmaceuticals. It navigates pre-clinical and clinical pathways to address a range of diseases and medical conditions, positioning itself within the evolving specialty drug manufacturing sector.
What Is the Investment Thesis for NXEN?
Nexien BioPharma, Inc. is positioned within the specialized and evolving cannabinoid-based pharmaceutical market, focusing on the rigorous pre-clinical and clinical development of new drug candidates. The company's value drivers are intrinsically linked to its ability to successfully advance its pipeline through various clinical trial stages, culminating in regulatory approvals and subsequent commercialization. Key growth catalysts include positive data readouts from ongoing or future clinical trials, which could significantly de-risk its development programs and attract further investment or partnerships. Expansion into new therapeutic indications for its cannabinoid-based formulations also represents a substantial growth opportunity. However, the company operates with a market capitalization of $0.00B and a negative Beta of -0.85, indicating a micro-cap status and potentially inverse market correlation, which suggests high volatility and specific risk factors. Its status as an OTC-traded company, specifically on the 'OTC Other' tier, also introduces risks related to liquidity and disclosure. The investment thesis centers on the long-term potential of its specialized drug development efforts, contingent on achieving significant milestones in a highly regulated and capital-intensive industry.
Based on FMP financials and quantitative analysis
NXEN Key Highlights
Specialized focus on cannabinoid-based pharmaceuticals development, targeting various diseases and medical conditions.
- Operates within the pre-clinical and clinical pathways, indicating a long-term R&D-intensive business model.
- Company rebranded from Intiva BioPharma Inc. to Nexien BioPharma, Inc. in September 2018, signaling strategic evolution.
- Trades on the OTC market under the 'OTC Other' tier, reflecting its current market structure and disclosure environment.
- Reported market capitalization of $0.00B, highlighting its micro-cap status within the pharmaceutical sector.
Who Are NXEN's Competitors?
NXEN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
| CPHI CPHI | $0.66 | +0.61% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NXEN's Key Strengths?
Specialized focus on cannabinoid-based pharmaceuticals, a growing therapeutic area.
- Engagement in pre-clinical and clinical pathways, indicating a structured drug development approach.
- Potential for novel drug formulations addressing unmet medical needs.
- Agile structure as a smaller pharmaceutical company to adapt to market changes.
What Are NXEN's Weaknesses?
Market capitalization of $0.00B suggests limited financial resources for extensive R&D.
- Trading on the 'OTC Other' tier implies lower liquidity and transparency compared to major exchanges.
- Negative Beta of -0.85 indicates high volatility and potential inverse market correlation.
- Reliance on successful progression through lengthy and costly clinical trials.
What Are the Key Risks for NXEN?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- High regulatory hurdles and lengthy approval processes inherent in pharmaceutical development, particularly for cannabinoid-based drugs.
- Significant capital requirements for pre-clinical and clinical trials, with a risk of insufficient funding given the $0.00B market cap.
- Intense competition from established pharmaceutical companies and other biotech firms in the cannabinoid therapeutics space.
- Low liquidity and limited public disclosure associated with trading on the 'OTC Other' tier, posing challenges for investors.
- Clinical trial failures or adverse safety findings, which could lead to abandonment of drug candidates and substantial financial losses.
What Threats Does NXEN Face?
- Intense competition from larger pharmaceutical companies entering the cannabinoid space.
- Strict and evolving regulatory hurdles for cannabinoid-based drugs.
- High failure rates inherent in pharmaceutical R&D, leading to significant capital loss.
- Limited access to capital markets due to OTC listing and small market cap.
What Are NXEN's Competitive Advantages?
- Specialized expertise in cannabinoid formulation and development.
- Potential intellectual property (patents) protecting its drug candidates and processes.
- Regulatory know-how and experience in navigating pharmaceutical approval pathways.
- Early-mover advantage or established position in the emerging cannabinoid pharmaceutical market.
What Does NXEN Do?
Nexien BioPharma, Inc., headquartered in Glendale, Colorado, operates as a pharmaceutical company dedicated to advancing cannabinoid-based therapeutics. The company's core activities encompass the formulation, development, and eventual commercialization of these specialized pharmaceuticals. Its strategic focus involves navigating the rigorous pre-clinical and clinical trial pathways required for regulatory approval, with the ultimate goal of bringing novel treatments to market for a diverse array of diseases, medical conditions, and disorders. The company's journey began under the name Intiva BioPharma Inc., before undergoing a strategic rebranding and changing its name to Nexien BioPharma, Inc. in September 2018. This name change marked a pivotal moment in its corporate evolution, signaling a refined focus or expanded scope within the biopharmaceutical landscape. Nexien BioPharma's operational model is deeply rooted in research and development, aiming to unlock the therapeutic potential of cannabinoids, which represent a distinct and increasingly recognized area within modern medicine. By concentrating on this niche, the company positions itself within the specialty pharmaceutical segment, requiring significant investment in scientific expertise, regulatory compliance, and clinical validation to establish its product pipeline and market presence. Its efforts are directed towards addressing unmet medical needs through innovative drug candidates, contributing to the broader healthcare sector's advancements.
What Products and Services Does NXEN Offer?
- Formulates cannabinoid-based pharmaceuticals for medical applications.
- Develops new drug candidates through pre-clinical research.
- Conducts clinical trials to test the safety and efficacy of its pharmaceutical products.
- Aims for commercialization of approved cannabinoid-based drugs.
- Focuses on treating various diseases, medical conditions, and disorders.
- Operates within the highly regulated pharmaceutical industry.
- Specializes in a niche area of drug manufacturing: cannabinoid therapeutics.
How Does NXEN Make Money?
- Research and development of cannabinoid-based drug candidates.
- Seeking regulatory approvals (e.g., FDA) for its pharmaceutical products.
- Potential commercialization and sales of approved drugs, either directly or through partnerships.
- Monetization of intellectual property through licensing or milestone payments from collaborations.
What Industry Does NXEN Operate In?
Nexien BioPharma, Inc. operates within the Drug Manufacturers - Specialty & Generic industry, with a distinct focus on cannabinoid-based pharmaceuticals. This segment of the healthcare sector is characterized by high research and development costs, stringent regulatory pathways, and significant intellectual property considerations. The broader pharmaceutical market is experiencing trends such as increasing demand for personalized medicine, a shift towards biologics and specialty drugs, and growing investment in novel therapeutic areas. Within this landscape, cannabinoid-based therapeutics represent an emerging, yet rapidly expanding, niche driven by evolving scientific understanding and regulatory frameworks. Nexien BioPharma's positioning as a developer in this specific area places it among companies seeking to capitalize on the therapeutic potential of cannabinoids, competing not only with other cannabinoid-focused firms but also with established pharmaceutical giants that may enter or acquire assets in this space. The competitive environment demands continuous innovation, efficient clinical execution, and strategic market access planning.
Who Are NXEN's Key Customers?
- Patients suffering from diseases and conditions treatable by cannabinoid-based pharmaceuticals.
- Healthcare providers (doctors, hospitals) prescribing or administering its approved drugs.
- Pharmaceutical distributors and pharmacies for product distribution.
- Potential pharmaceutical partners for co-development or licensing agreements.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Nexien BioPharma, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Nexien BioPharma, Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Nexien BioPharma, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Glendale, US. The company is led by CEO Richard S. Greenberg. NXEN has traded publicly since 2017.
Insider Activity
12 transactions · 0 purchases, 0 sales, 12 other transactions · 3 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
NXEN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
NXEN Latest News
-
Zacks Industry Outlook WPP, Nexxen and Quad/Graphics
Zacks · Aug 7, 2026
NXEN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NXEN.
Price Targets
Wall Street price target analysis for NXEN.
NXEN MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NXEN; grades run from A+ (80-100) to F (below 30).
NXEN OTC Market Information
Nexien BioPharma, Inc. trades on the 'OTC Other' tier, which represents the lowest tier of the OTC Markets Group's three marketplaces. Unlike companies listed on major exchanges like NYSE or NASDAQ, 'OTC Other' companies do not meet minimum financial standards, disclosure requirements, or corporate governance standards to qualify for OTCQX or OTCQB. This tier includes companies that may not be current in their disclosures or have limited public information available. Investors typically face higher risks due to the lack of transparent financial reporting and regulatory oversight compared to higher tiers or listed exchanges.
- OTC Tier: OTC Other
- Limited public disclosure and transparency, making due diligence challenging.
- Extremely low trading volume and liquidity, leading to difficulty in buying or selling shares.
- Increased susceptibility to market manipulation due to low float and limited oversight.
- Higher volatility and price fluctuations compared to stocks on major exchanges.
- Potential for delisting or further deterioration of trading status if disclosure remains unknown or inadequate.
- Verify the company's current financial statements and audit reports, if available, from independent sources.
- Research any recent corporate actions, such as reverse stock splits or share issuances, that could impact ownership.
- Investigate the management team's background and track record beyond what is publicly stated.
- Assess the viability and progress of its cannabinoid-based pharmaceutical pipeline through independent scientific reviews.
- Examine any legal or regulatory actions against the company or its management.
- Understand the current shareholder structure and any significant institutional holdings.
- Evaluate the company's capital raising history and future funding needs.
- The company has a stated focus on a specific, albeit emerging, pharmaceutical segment (cannabinoid-based drugs).
- It has undergone a formal name change, indicating some level of corporate activity and strategic evolution.
- The company is headquartered in Glendale, Colorado, suggesting a physical operational base.
- Its stated pursuit of pre-clinical and clinical pathways aligns with standard pharmaceutical development processes.
- The presence of a named CEO, Richard S. Greenberg, provides a point of contact for leadership.
Nexien BioPharma, Inc. Healthcare Stock: Key Questions Answered
What are the main risks for NXEN?
Nexien BioPharma, Inc. faces several significant risks inherent to its industry and market position. As a pharmaceutical company, it is exposed to the high costs, long timelines, and high failure rates associated with drug development and clinical trials.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial data available, particularly for specific revenue, profit, or balance sheet metrics beyond market cap.
- CEO background and track record are not provided in the source data, leading to 'Unknown' entries.
- Specific details on drug pipeline stages (e.g., Phase 1, 2, 3) are not available in the source data, requiring general statements about pre-clinical and clinical pathways.